Guide · Updated 2026-06-28
340B Drug Pricing and Wound Skin Substitutes
Some Q-coded skin substitutes are eligible for 340B pricing; many are not. Misclassification creates compliance exposure and audit risk. Verify eligibility per product, per quarter.
Eligibility by classification
340B applies to outpatient drugs as defined in the Medicaid Drug Rebate Program (MDRP). Skin substitutes classified as biological drugs (some Q-coded products) may qualify; those classified as devices or Section 361 HCT/Ps generally do not. Confirm each product's MDRP status with the manufacturer.
Operational compliance
Covered entities must prevent duplicate discounts (340B + Medicaid rebate) and avoid diversion (340B product dispensed to ineligible patient). Skin substitutes used in outpatient wound clinics typically flow through the same compliance workflow as 340B-eligible biologics.
Procurement leverage
For 340B-eligible products at qualifying entities, the discount can exceed 25% off ASP. This is the single largest pricing lever in AWC procurement at FQHCs and DSH hospitals.
Key takeaways
- Not all skin substitutes qualify for 340B — verify by product.
- Compliance: no duplicate discounts, no diversion.
- Where eligible, discount can exceed 25% off ASP.
More from the playbook
- Formulary Management for Bioengineered Tissues
- Negotiating Wound Care Vendor Rebates
- Reducing Biological Wound Graft Waste in the OR and Wound Center
- Inpatient to Outpatient Wound Graft Billing Transition
- Cold Chain Logistics for Cryopreserved Wound Grafts
- MAC Jurisdiction Coverage Variance for Skin Substitutes
Part of the 2026 Advanced Wound Graft Procurement Playbook.